Schering Caught In WHI Wake

Disturbing news from a major hormone study, bad regulatory luck, and a botched attempt to reassure German gynecologists have hurt Schering's HRT business. Yet the company hopes to use its risk-lowering franchise strategy to distinguish its HRT products from competitors'.

After years of impressive growth, Germany's Schering AG has had a tough few months. The 17,000-patient Women's Health Initiative (WHI) study in July highlighted an increased risk of breast cancer, heart attacks and stroke among patients taking Wyeth 's combined estrogen/progestin hormone replacement therapy (HRT) Prempro. Addressing the long-term risks of HRT, the study was terminated three years early because of the breast cancer findings.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.